A 55-year-old man presented with fever, night sweats, and weight loss of about 20 lbs. in the prior 6 months. Physical examination revealed multiple cervical, axillary, and inguinal lymphadenopathy. The spleen was enlarged. A complete blood count revealed leukocytosis with absolute lymphocytosis: 30,000/μL. Peripheral blood-flow cytometric analysis showed a clonal lymphocyte population with immunophenotypes positive for CD5, CD20(dim), and monotypic kappa light chain. Fluorescence in situ hybridization (FISH) analysis revealed del(11q22.3), but negative for t(11:14). What should be used to treat his chronic lymphocytic leukemia (CLL) disease?

CLL patients with del(11q22–11q23) represent a distinct clinical subset. This genomic aberration occurs in approximately 20% of patients with advanced CLL. These patients are usually younger than the typical CLL patient (median age, 59 years1 ), and often have extensive lymphadenopathies at the time of diagnosis.1–3  The clinical course of patients with the 11q deletion is usually characterized by rapid disease progression with shorter treatment-free survival; a shorter overall survival has been reported in patients younger than 55 years.2,4  Therefore, the choice of the initial treatment is particularly important in these young patients.

In the last decade, therapies including the purine analog have emerged as the main therapies for CLL disease. The superiority of single therapy with fludarabine over chlorambucil has been established for response rate, progression-free survival (PFS), and, most recently, overall survival, despite crossover studies between the two arms.5,6  Three independent studies have demonstrated that fludarabine + cyclophosphamide combination therapies (FC) achieve a better response rate and PFS compared with fludarabine alone, although no significant difference was reported in terms of overall survival.7–9  Subsequently, single-center phase II clinical trials evaluated “chemoimmunotherapy” (CIT) combining a purine analog with or without the alkylating agent cyclophosphamide and the anti-CD20 antibody, rituximab.10,11,16–18  High response rates were obtained with CIT combinations, and in many centers these strategies have become first-line therapies for CLL. Recently, the German CLL study group has reported the results of a study comparing fludarabine + cyclophosphamide + rituximab (FCR) with FC, and demonstrated that FCR is superior to FC in terms of response rate and PFS; there was also a trend toward better survival in the FCR group.12  However, the importance of cyclophosphamide in CIT compared with combination therapies of purine analog and rituximab has not been clearly defined.

In this review, we focus on the results of purine analog-based front-line therapies of CLL patients with del(11q22–11q23). We therefore performed a literature search combining the National Library of Medicine's Medical Subject Heading (MeSH) terms “leukemia, lymphocytic, chronic, B-cell” and “cyclophosphamide” and limiting the search to human clinical trials in English. This strategy yielded 94 citations. When “purine analog” was used as a key word in the combination search, 58 citations were yielded. Among these, there are five randomized, controlled trials. Three addressed the efficacy of FC compared with fludarabine in front-line therapies for CLL. A search of PubMed and ASH annual meeting abstracts revealed three subsequent analyses including patients with deletion of 11q. Table 1 provides the details of the three randomized, controlled trials and their subsequent analysis.

In these three trials, patients with deletion of 11q had shorter PFS. In the Leukemia Research Foundation CLL4 trial and the German CLL study, del(11q) patients had statistically significant longer PFS or higher response rates when treated with FC compared with their counterparts treated with fludarabine alone. Additionally, although PFS in del(11q) patients treated with FC appeared longer compared with similar patients treated with fludarabine in the E2997 trial, it did not reach statistical significance after approximately 3 years of follow-up.

Several studies have addressed the clinical efficacy of CIT; the details of these phase II and III trials are summarized in Table 2. Interestingly, in PCR trials performed by the Mayo Clinic and the Ohio State University, subgroup analysis revealed that patients with the 11q deletion had similar PFS compared with the whole group. While these results were compared with the PR trial conducted at the same institutions, the addition of cyclophosphamide appeared to confer a higher overall and complete remission rate and longer duration of response. This finding was further supported by a recent retrospective analysis performed at M.D. Anderson Cancer Center on a group of 69 CLL patients with the 11q deletion. The del(11q22.3) patients treated with FCR had a 100% response rate and high PFS, suggesting that CIT therapy could overcome the adverse prognosis of the 11q deletion.1  A large randomized intergroup trial comparing FCR with FR therapy is currently ongoing, and the results may further clarify the role played by alkylating agents in CIT combination therapy in this subgroup of patients.

In summary, there is evidence from a subgroup analysis of randomized clinical trials that the addition of alkylating agents, in particular cyclophosphamide, to fludarabine is associated with superior response rate and longer PFS in patients with the 11q deletion (Grade 1A). While data on response duration and overall survival still indicate that this group of patients has an inferior outcome compared with patients with favorable genomic abnormalities (Grade 1A), this suggest that further intensification strategies should be evaluated in this population, and the attainment of a response to the initial therapy is a relevant clinical end point. CIT therapy containing cyclophosphamide achieves longer PFS than the combination therapy with the purine analog and rituximab (Grade 1C). For high-risk CLL patients with del(11q22.3), complete CIT therapy could overcome the adverse prognosis of the 11q deletion (Grade 1C). Therefore, in fit CLL patients, we recommend that cyclophosphamide is included in the CIT therapy of patients with del(11q) (Grade 1C).

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Off-label drug use: None disclosed.

Alessandra Ferrajoli, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd., Houston, TX 77030; Phone: 713-792-2063; Fax: 713-745-4612; e-mail: aferrajo@mdanderson.org

1
Tsimberidou
AM
Tam
C
Abruzzo
LV
et al
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
Cancer
2009
115
373
380
2
Dohner
H
Stilgenbauer
S
James
MR
et al
11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis
Blood
1997
89
2516
2522
3
Zenz
T
Frohling
S
Mertens
D
Dohner
H
Stilgenbauer
S
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)
Best Pract Res Clin Haematol
2010
23
71
84
4
Dohner
H
Stilgenbauer
S
Benner
A
et al
Genomic aberrations and survival in chronic lymphocytic leukemia
N Engl J Med
2000
343
1910
1916
5
Rai
KR
Peterson
BL
Appelbaum
FR
et al
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
N Engl J Med
2000
343
1750
1757
6
Rai
KR
Peterson
BL
Appelbaum
FR
et al
Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL) [Abstract]
Blood
2009
114
536
7
Eichhorst
BF
Busch
R
Hopfinger
G
et al
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood
2006
107
885
891
8
Flinn
IW
Neuberg
DS
Grever
MR
et al
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
J Clin Oncol
2007
25
793
798
9
Catovsky
D
Richards
S
Matutes
E
et al
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
Lancet
2007
370
230
239
10
Keating
MJ
O'Brien
S
Albitar
M
et al
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
J Clin Oncol
2005
23
4079
4088
11
Kay
NE
Geyer
SM
Call
TG
et al
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Blood
2007
109
405
411
12
Hallek
M
Fingerle-Rowson
G
Fink
A-M
et al
First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [Abstract]
Blood
2009
114
535
13
Stilgenbauer
S
Eichhorst
B
Busch
R
et al
Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC)–comprehensive analysis of the CLL4 Trial of the GCLLSG [Abstract]
Blood
2008
112
14
Grever
MR
Lucas
DM
Dewald
GW
et al
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
J Clin Oncol
2007
25
799
804
15
Oscier
D
Wade
R
Davis
Z
et al
Chronic Lymphocytic Leukaemia Working Group, UK National Cancer ResearchInstitute
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
Haematologica
2010
10
95
10
1705
1712
16
Byrd
JC
Peterson
BL
Morrison
VA
et al
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood
2003
101
6
14
17
Woyach
JA
Ruppert
AS
Heerema
NA
et al
Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB Study 9712 [Abstract]
Blood
2009
114
539
18
Kay
NE
Wu
W
Kabat
B
et al
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
Cancer
2010
116
2180
2187